• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HPV16 疫苗接种和未接种年轻女性的非翻译调控区、L1 和 E6 基因中 HPV16 变异的比较分析:评估疫苗效力和病毒多样性。

Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity.

机构信息

National Institute for Public Health and the Environment, Centre for Infectious Disease Control, 3721MA Bilthoven, The Netherlands.

Department of Pathology, Amsterdam UMC Location Vrije Universiteit Amsterdam, 1007MB Amsterdam, The Netherlands.

出版信息

Viruses. 2024 Aug 29;16(9):1381. doi: 10.3390/v16091381.

DOI:10.3390/v16091381
PMID:39339857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11435937/
Abstract

HPV16 is occasionally detected in vaccinated women who received the bivalent HPV16/18 vaccine, usually at low viral loads. This study explored potential differences in HPV16 variants between vaccinated and unvaccinated women. HPV16-postive viral loads were detected in 1.9% (17/875) and 13% (162/760) of vaccinated and unvaccinated women, respectively, showcasing the vaccine's high efficacy. The L1, E6, and URR regions of HPV16 were sequenced from genital swabs from 16 vaccinated and 25 unvaccinated women in the HAVANA (HPV Among Vaccinated And Non-vaccinated Adolescents) study. The majority of HPV16 variants from vaccinated and unvaccinated women clustered similarly with sub-lineages A1 and A2. Additionally, a separate cluster within lineage A was found, with the variants sharing the L1-located SNP A753G (synonymous) and the URR-located SNP T340C, which did not occur in the other variants. Furthermore, four variants from vaccinated women had relatively long branches, but were not characterized by specific SNPs. The frequency of G712A in the URR was the only SNP observed to be marginally higher among vaccinated women than unvaccinated women. Non-synonymous SNPs T266A in the FG-loop of L1 and L83V in E6 were common among variants from vaccinated and unvaccinated women, but present in similar frequencies. In conclusion, the detection of HPV16 in vaccinated (and unvaccinated) women seemed to be the result of random circulation within this study population.

摘要

HPV16 偶尔会在接种了二价 HPV16/18 疫苗的女性中被检测到,通常病毒载量较低。本研究探讨了接种疫苗和未接种疫苗女性之间 HPV16 变体的潜在差异。在接种组和未接种组中,HPV16 阳性病毒载量分别为 1.9%(17/875)和 13%(162/760),显示出疫苗的高功效。在 HAVANA(HPV 在接种和未接种青少年中的研究)研究中,从 16 名接种疫苗和 25 名未接种疫苗的女性的生殖器拭子中对 HPV16 的 L1、E6 和 URR 区进行了测序。接种疫苗和未接种疫苗的女性的 HPV16 变体主要以亚谱系 A1 和 A2 聚类相似。此外,还在谱系 A 内发现了一个单独的聚类,变体共享位于 L1 的 SNP A753G(同义)和位于 URR 的 SNP T340C,而其他变体则没有。此外,来自接种疫苗的女性的四个变体具有相对较长的分支,但没有被特定的 SNP 所描述。在 URR 中观察到的 G712A 频率是唯一一个在接种组中比未接种组略高的 SNP。L1 的 FG-环中的非同义 SNP T266A 和 E6 中的 L83V 在接种疫苗和未接种疫苗的女性中变体中很常见,但出现的频率相似。总之,在接种疫苗的(和未接种疫苗的)女性中检测到 HPV16 似乎是该研究人群中随机循环的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/8c6bda3422eb/viruses-16-01381-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/67e58434a67b/viruses-16-01381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/4a3f9dd60bd9/viruses-16-01381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/e824d3e631fa/viruses-16-01381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/010677d2ec2f/viruses-16-01381-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/8c6bda3422eb/viruses-16-01381-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/67e58434a67b/viruses-16-01381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/4a3f9dd60bd9/viruses-16-01381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/e824d3e631fa/viruses-16-01381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/010677d2ec2f/viruses-16-01381-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e9b/11435937/8c6bda3422eb/viruses-16-01381-g005.jpg

相似文献

1
Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity.HPV16 疫苗接种和未接种年轻女性的非翻译调控区、L1 和 E6 基因中 HPV16 变异的比较分析:评估疫苗效力和病毒多样性。
Viruses. 2024 Aug 29;16(9):1381. doi: 10.3390/v16091381.
2
Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.针对人乳头瘤病毒 16(HPV16)和 HPV18 的 E6 和 E7 蛋白的 DNA 疫苗的开发,用于与重组痘苗增强和 PD-1 抗体联合免疫治疗。
mBio. 2021 Jan 19;12(1):e03224-20. doi: 10.1128/mBio.03224-20.
3
Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.高危型人乳头瘤病毒衣壳 L1 基因的全球遗传变异及其对疫苗效率的影响。
Gene. 2021 May 25;782:145533. doi: 10.1016/j.gene.2021.145533. Epub 2021 Feb 23.
4
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.用16型人乳头瘤病毒L2E7E6融合蛋白对健康志愿者进行疫苗接种可诱导产生能中和多种乳头瘤病毒的血清抗体。
Cancer Res. 2006 Dec 1;66(23):11120-4. doi: 10.1158/0008-5472.CAN-06-2560.
5
Identification of human papillomavirus type 16 variants circulating in the Calabria region by sequencing and phylogenetic analysis of HPV16 from cervical smears.通过对宫颈涂片 HPV16 进行测序和系统进化分析,鉴定卡拉布里亚地区流行的人乳头瘤病毒 16 型变异体。
Infect Genet Evol. 2019 Mar;68:185-193. doi: 10.1016/j.meegid.2018.12.024. Epub 2018 Dec 20.
6
HPV16 L1 diversity and its potential impact on the vaccination-induced immunity.HPV16 L1 多样性及其对疫苗诱导免疫的潜在影响。
Gene. 2020 Jul 15;747:144682. doi: 10.1016/j.gene.2020.144682. Epub 2020 Apr 15.
7
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.使用GPI-0100佐剂的HPV16 L2E6E7融合蛋白疫苗接种可引发保护性体液免疫和细胞介导免疫。
Vaccine. 2009 Feb 11;27(7):1040-9. doi: 10.1016/j.vaccine.2008.11.099. Epub 2008 Dec 16.
8
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study.HPV 疫苗接种状况及 HPV16/18 感染韩国女性中的有效性(2010-2021 年):一项回顾性研究。
J Gynecol Oncol. 2024 Sep;35(5):e56. doi: 10.3802/jgo.2024.35.e56. Epub 2024 Jan 22.
9
Association of human papillomavirus type 16 and its genetic variants with cervical lesion in Korea.韩国16型人乳头瘤病毒及其基因变异与宫颈病变的关联
APMIS. 2016 Nov;124(11):950-957. doi: 10.1111/apm.12592. Epub 2016 Aug 21.
10
Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions.基于E6和L1基因的突尼斯宫颈病变女性人乳头瘤病毒(HPV)16和HPV18变体的系统发育与分类
Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3361-3366. doi: 10.31557/APJCP.2018.19.12.3361.

本文引用的文献

1
Protein-DNA Interactions Regulate Human Papillomavirus DNA Replication, Transcription, and Oncogenesis.蛋白质-DNA 相互作用调控人乳头瘤病毒 DNA 复制、转录和致癌作用。
Int J Mol Sci. 2023 May 9;24(10):8493. doi: 10.3390/ijms24108493.
2
Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.二价人乳头瘤病毒(HPV)疫苗两剂和三剂接种对年轻女性HPV清除性和持续性感染的患病率及病毒载量的影响
J Infect Dis. 2023 Oct 18;228(8):1012-1022. doi: 10.1093/infdis/jiad080.
3
Human papillomavirus genomics: Understanding carcinogenicity.
人乳头瘤病毒基因组学:致癌性解析。
Tumour Virus Res. 2023 Jun;15:200258. doi: 10.1016/j.tvr.2023.200258. Epub 2023 Feb 20.
4
Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas.HPV16 L1 和 L2 基因在不同地理区域的突变特征。
Viruses. 2022 Dec 31;15(1):141. doi: 10.3390/v15010141.
5
Characterization of Human Papillomavirus 16 from Kinshasa (Democratic Republic of the Congo)-Implications for Pathogenicity and Vaccine Effectiveness.来自金沙萨(刚果民主共和国)的人乳头瘤病毒16型的特征——对致病性和疫苗有效性的影响
Microorganisms. 2022 Dec 16;10(12):2492. doi: 10.3390/microorganisms10122492.
6
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.2020 年全球宫颈癌发病率和死亡率估计:世卫组织全球消除宫颈癌倡议的基线分析。
Lancet Glob Health. 2023 Feb;11(2):e197-e206. doi: 10.1016/S2214-109X(22)00501-0. Epub 2022 Dec 14.
7
Longitudinal follow-up of HPV16 sequence after cervical infection: Low intrahost variation and no correlation with clinical evolution.宫颈感染后 HPV16 序列的纵向随访:宿主内变异低,与临床演变无关。
J Med Virol. 2022 Nov;94(11):5512-5518. doi: 10.1002/jmv.27978. Epub 2022 Jul 20.
8
Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan.调查日本 HPV16 变体的多样性和与预防 HPV 相关的口咽癌相关的 L1 抗原区域。
Auris Nasus Larynx. 2022 Dec;49(6):1033-1041. doi: 10.1016/j.anl.2022.04.006. Epub 2022 Apr 28.
9
An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy.人乳头瘤病毒疫苗的最新进展:历史、类型、保护和疗效。
Front Immunol. 2022 Jan 27;12:805695. doi: 10.3389/fimmu.2021.805695. eCollection 2021.
10
Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix® or Gardasil® vaccine.在接种佳达修®或卉妍康®疫苗后长达 7 年内,对疫苗(HPV6/11/16/18)和非疫苗(HPV31/33/45/52/58)HPV 抗原的结合抗体水平。
Vaccine. 2022 Feb 23;40(9):1198-1202. doi: 10.1016/j.vaccine.2022.01.041. Epub 2022 Feb 1.